Handelsbanken Fonder Ab Biotechnology

Handelsbanken Fonder Ab

$24.3 Billion
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
LGND Ligand Pharmaceuticals Inc	$2.32B	$700,000 0.0% of portfolio	6,658	Q1 2025 Added 13.66%
PTGX Protagonist Therapeutics, Inc	$2.77B	$696,000 0.0% of portfolio	14,400	Q1 2025 Reduced 18.18%
APLS Apellis Pharmaceuticals, Inc.	$2.2B	$669,000 0.0% of portfolio	30,600	Q4 2024 Added 10.87%
AGIO Agios Pharmaceuticals, Inc.	$2.21B	$566,000 0.0% of portfolio	19,323	Q4 2024 Added 8.42%
IDYA Ideaya Biosciences, Inc.	$1.06B	$562,000 0.0% of portfolio	34,300	Q1 2025 Added 35.57%
BEAM Beam Therapeutics Inc.	$1.44B	$537,000 0.0% of portfolio	27,500	Q4 2024 Reduced 3.51%
ARWR Arrowhead Pharmaceuticals, Inc.	$2B	$525,000 0.0% of portfolio	41,200	Q4 2024 Added 15.41%
DNLI Denali Therapeutics Inc.	$1.95B	$521,000 0.0% of portfolio	38,300	Q4 2024 Reduced 3.04%
AUPH Aurinia Pharmaceuticals Inc.	$1.29B	$488,000 0.0% of portfolio	60,700	Q3 2024 Added 13.25%
EWTX Edgewise Therapeutics, Inc.	$867M	$480,000 0.0% of portfolio	21,800	Q4 2024 New
KYMR Kymera Therapeutics, Inc.	$2.54B	$452,000 0.0% of portfolio	16,500	Q4 2024 Reduced 4.62%
HRMY Harmony Biosciences Holdings, Inc.	$2.16B	$448,000 0.0% of portfolio	13,500	Q4 2024 Added 19.47%
MLTX Moon Lake Immunotherapeutics	$1.81B	$434,000 0.0% of portfolio	11,100	Q4 2024 Reduced 14.62%
RXRX Recursion Pharmaceuticals, Inc.	$996M	$389,000 0.0% of portfolio	73,600	Q4 2024 Added 5.9%
CLDX Celldex Therapeutics, Inc.	$1.07B	$383,000 0.0% of portfolio	21,100	Q4 2024 Added 52.9%
IMVT Immunovant, Inc.	$3.55B	$357,000 0.0% of portfolio	20,900	Q3 2024 Added 29.01%
VERA Vera Therapeutics, Inc.	$643M	$331,000 0.0% of portfolio	13,800	Q3 2024 Added 18.97%
JANX Janux Therapeutics, Inc.	$1.16B	$324,000 0.0% of portfolio	12,000	Q4 2024 New
XNCR Xencor Inc	$541M	$283,000 0.0% of portfolio	26,600	Q4 2024 Added 14.16%
IBRX Immunity Bio, Inc.	$1.13B	$278,000 0.0% of portfolio	92,300	Q4 2024 Added 71.24%
GERN Geron Corp	$487M	$270,000 0.0% of portfolio	169,900	Q4 2024 New
PRTA Prothena Corp Public LTD CO	$304M	$259,000 0.0% of portfolio	20,900	Q4 2024 Added 35.71%
DAWN Day One Biopharmaceuticals, Inc.	$477M	$250,000 0.0% of portfolio	31,500	Q4 2024 Added 16.67%
NTLA Intellia Therapeutics, Inc.	$899M	$247,000 0.0% of portfolio	34,700	Q4 2024 Added 7.1%
ACIU Ac Immune Sa	$173M	$243,000 0.0% of portfolio	130,000	Q1 2025 Reduced 13.33%
IOVA Iovance Biotherapeutics, Inc.	$369M	$242,000 0.0% of portfolio	72,700	Q4 2024 Reduced 2.81%
DYN Dyne Therapeutics, Inc.	$487M	$235,000 0.0% of portfolio	22,500	Q4 2024 Added 16.58%
RCUS Arcus Biosciences, Inc.	$680M	$195,000 0.0% of portfolio	24,800	Q4 2024 Added 11.21%
ARVN Arvinas, Inc.	$413M	$160,000 0.0% of portfolio	22,825	Q4 2024 Added 16.9%
RCKT Rocket Pharmaceuticals, Inc.	$253M	$154,000 0.0% of portfolio	23,100	Q4 2024 Added 26.92%
AUTL Autolus Therapeutics PLC	$220M	$114,000 0.0% of portfolio	73,300	Q4 2024 Added 30.89%
KROS Keros Therapeutics, Inc.	$370M	$110,000 0.0% of portfolio	10,800	Q4 2024 Added 11.34%
MRVI Maravai Lifesciences Holdings, Inc.	$330M	$99,000 0.0% of portfolio	44,600	Q3 2024 Added 35.56%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.